Australia's most trusted
source of pharma news
Sunday, 30 June 2024
Posted 22 May 2024 PM
Overnight AstraZeneca unveiled its "bold ambition" to deliver US$80 billion in total revenue by the end of decade with the launch of 20 new medicines.
In announcing "the new era of growth" AstraZeneca's CEO, Pascal Soriot said many of the products have "the potential to generate more than US$5 million in peak year revenues".
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.